Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above 200 Day Moving Average – Should You Sell?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.37 and traded as high as $7.97. Vanda Pharmaceuticals shares last traded at $7.93, with a volume of 957,741 shares.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VNDA. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 8th. Jefferies Financial Group increased their price target on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research report on Wednesday, December 31st. B. Riley lifted their price objective on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. HC Wainwright upped their target price on Vanda Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Finally, UBS Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 5th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.63.

Vanda Pharmaceuticals Trading Up 2.9%

The firm’s 50-day simple moving average is $6.50 and its 200 day simple moving average is $5.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.12 and a quick ratio of 3.10. The firm has a market capitalization of $468.66 million, a price-to-earnings ratio of -5.58 and a beta of 0.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.82%. The business had revenue of $56.26 million during the quarter, compared to the consensus estimate of $58.73 million. Equities analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in VNDA. SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at approximately $95,000. Wealth Enhancement Advisory Services LLC lifted its stake in Vanda Pharmaceuticals by 33.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,413 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 5,913 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Vanda Pharmaceuticals by 16.5% in the third quarter. JPMorgan Chase & Co. now owns 199,893 shares of the biopharmaceutical company’s stock valued at $997,000 after buying an additional 28,238 shares in the last quarter. Krensavage Asset Management LLC grew its stake in shares of Vanda Pharmaceuticals by 15.2% during the third quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock worth $5,890,000 after buying an additional 155,505 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new position in shares of Vanda Pharmaceuticals during the third quarter worth $285,000. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.